Evidence map›Paper›PMID 24470546›Full record

Trial reportNeuro-oncology2014

Phase II trial of patupilone in patients with brain metastases from breast cancer.

David M Peereboom, Conleth Murphy, Manmeet S Ahluwalia, Alison Conlin, April Eichler, Catherine Van Poznak, Joseph Baar, Paul Elson, Andrew D Seidman

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Epothilones as Natural Compounds for Novel Anticancer Drugs Development.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Improved i.p. drug delivery with bioadhesive nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

David M PeereboomCleveland Clinic Lerner College of Medicine, Case Western Reserve University (D.M.P., M.S.A.); The Rose Ella Burkhardt Brain Tumor and NeuroOncology Center, Neurological Institute, Cleveland Clinic (D.M.P., M.S.A.); Taussig Cancer Institute, Cleveland Clinic (D.M.P., M.S.A., P.E.); Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio(P.E.); Memorial Sloan-Kettering Cancer Center, New York, New York(C.M., A.C., A.D.S.); Massachusetts General Hospital, Boston, Massachusetts(A.E.); Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan(C.V.P.); Seidman Cancer Center of University Hospitals, Case Medical Center, Cleveland, Ohio(J.B.).
Conleth Murphy
Manmeet S Ahluwalia
Alison Conlin
April Eichler
Catherine Van Poznak
Joseph Baar
Paul Elson
Andrew D Seidman
Michigan Center for Translational Pathology · USCase Western Reserve University · USCleveland Clinic Lerner College of Medicine · USMemorial Sloan Kettering Cancer Center · USUniversity Hospitals Case Medical Center · USUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor patients with progressive breast cancer brain metastasis (BCBM) after whole brain radiotherapy (WBRT), few options exist. Patupilone is an epothilone that crosses the blood-brain barrier. We hypothesized that patupilone would produce a 35% 3-month CNS progression-free survival in women with BCBM after WBRT.

methodsThis multicenter phase II trial included 2 cohorts. Group A included women with progressive BCBM after WBRT. Group B was an exploratory cohort of patients with either leptomeningeal metastases or untreated brain metastases. The primary goal was to observe a 35% 3-month CNS progression-free survival in Group A. The sample size was 45 for Group A and 10 for Group B. Patients received patupilone 10 mg/m(2) once every 3 weeks until progression. Responses were scored according to the Macdonald criteria.

resultsFifty-five patients (45 in Group A, 10 in Group B) enrolled. In Group A, the 3-month CNS progression-free survival was 27%, the median overall survival was 12.7 months, and the overall response rate was 9%. In Group B, which enrolled 5 patients with leptomeningeal disease and 5 with no prior WBRT, no responses occurred and 8 patients had CNS progression before 3 months. Systemic responses occurred in 15% of patients, including a complete response in liver metastases. Diarrhea occurred in 87% of patients; 25% had grade 3 and 4 adverse events.

conclusionsPatupilone in patients with BCBM did not meet the efficacy criteria and had significant gastrointestinal toxicity. Further study of brain-penetrant agents is warranted for patients with CNS metastases from breast cancer.

Indexed as

AdultAgedAntineoplastic AgentsBrain NeoplasmsBreast NeoplasmsCohort StudiesEpothilonesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingPrognosisSurvival RateAntineoplastic Agentsepothilone BEpothilonesbrain metastasesbreast cancerchemotherapyepothilonepatupilone

Identifiers

PMID24470546
PMCPMC3956359
OpenAlexW2157342168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.